Partners

Strong partnerships complement our core team’s discovery and pre-GMP production expertise. PROGENITER has established an extensive network of partnerships between public and private entities.

This initiative was undertaken thanks in part to funding from the Canada Biomedical Research Fund and the Biosciences Research Infrastructure Fund.

Academic Partners

  • Canada’s Immuno-Engineering and Biomanufacturing Hub

    Canada’s Immuno-Engineering and Biomanufacturing Hub

    CIEBH is a new UBC-led national research hub aimed at strengthening Canada’s pandemic preparedness and developing lifesaving new medicines that will transform the health of Canadians.

  • Simon Fraser University

    Simon Fraser University

    As Canada’s engaged university, SFU works with communities, organizations and partners to create, share and embrace knowledge that improves life and generates real change. We deliver a world-class education with lifelong value that shapes change-makers, visionaries and problem-solvers. We connect research and innovation to entrepreneurship and industry to deliver sustainable, relevant solutions to today’s problems.…

  • The University of British Columbia

    The University of British Columbia

    The University of British Columbia is a global centre for research and teaching, consistently ranked among the top public universities in the world. Since 1915, UBC’s entrepreneurial spirit has embraced innovation and challenged the status quo. UBC encourages its students, staff and faculty to challenge convention, lead discovery and explore new ways of learning. At…

Industry Partners

  • AbCellera

    AbCellera

    AbCellera (Nasdaq: ABCL) discovers and develops antibody medicines for indications across therapeutic areas including cancer, metabolic and endocrine conditions, and autoimmune disorders. AbCellera’s engine integrates technology, data science, infrastructure, and interdisciplinary teams to solve the most challenging antibody discovery problems. AbCellera is focused on advancing an internal pipeline of first-in-class and best-in-class programs and collaborating on…

  • Amgen

    Amgen

    Amgen discovers, develops, manufactures and delivers innovative medicines to help millions of patients in their fight against some of the world’s toughest diseases. More than 40 years ago, Amgen helped to establish the biotechnology industry and remains on the cutting-edge of innovation, using technology and human genetic data to push beyond what’s known today. Amgen is advancing a broad and…

  • Gandeeva Therapeutics

    Gandeeva Therapeutics

    Gandeeva Therapeutics is a precision biotechnologycompany that is integrating the power of cryogenicelectron microscopy and machine learning to developdifferentiated therapeutics by targeting and modulatingkey protein interactions. Gandeeva has a robustpreclinical oncology pipeline targetingdifficult-to-treat cancers.

  • GSK

    GSK

    GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together.

  • Zymeworks

    Zymeworks

    Zymeworks is a global biotechnology company committed to the discovery, development, and commercialization of novel, multifunctional biotherapeutics. Zymeworks’ mission is to make a meaningful difference in the lives of people impacted by difficult-to-treat cancers and other diseases. The Company’s complementary therapeutic platforms and fully integrated drug development engine provide the flexibility and compatibility to precisely…

With gratitude, we acknowledge that the PROGENITER program and its partners, which include The University of British Columbia Faculty of Medicine and Simon Fraser University, are situated on the unceded traditional territories of the xʷməθkʷəy̓əm (Musqueam), Sḵwx̱wú7mesh (Squamish), and səlilwətaɬ (Tsleil-Waututh) Nations.

PROGENITER

2215 Wesbrook Mall
Vancouver, BC V6T 1Z3